News
The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).
Apr. 30, 2025 — Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback